Patents by Inventor Dalit Vaizel-Ohayon

Dalit Vaizel-Ohayon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptides for inhibiting chemokine binding to chemokine receptors
    Patent number: 8796227
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: August 5, 2014
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Peptides for inhibiting chemokine binding to chemokine receptors
    Patent number: 8383769
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: February 26, 2013
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • PEPTIDES FOR INHIBITING CHEMOKINE BINDING TO CHEMOKINE RECEPTORS
    Publication number: 20120028913
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Application
    Filed: October 17, 2011
    Publication date: February 2, 2012
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Peptides for inhibiting chemokine binding to chemokine receptors
    Patent number: 8039440
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: October 18, 2011
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Methods of inhibiting chemokine binding to chemokines receptors
    Publication number: 20100173848
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Application
    Filed: January 22, 2009
    Publication date: July 8, 2010
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Methods of inhibiting chemokine binding to chemokine receptors
    Patent number: 7488717
    Abstract: Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: February 10, 2009
    Assignee: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon
  • Novel chemokine binding peptides capable of modulating the biological activity of chemokines
    Publication number: 20040171552
    Abstract: Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
    Type: Application
    Filed: August 28, 2003
    Publication date: September 2, 2004
    Applicant: Biokine Therapeutics Ltd.
    Inventors: Amnon Peled, Orly Eizenberg, Dalit Vaizel-Ohayon